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Abstract
Background: Escherichia coli is a common cause of asymptomatic and symptomatic bacteriuria in hospitalized
patients. Asymptomatic bacteriuria (ASB) is frequently treated with antibiotics without a clear indication. Our goal
was to determine patient and pathogen factors suggestive of ASB.
Methods: We conducted a 12-month prospective cohort study of adult inpatients with E. coli bacteriuria seen at a
tertiary care hospital in St. Louis, Missouri, USA. Urine cultures were taken at the discretion of treating physicians.
Bacterial isolates were tested for 14 putative virulence genes using high-throughput dot-blot hybridization.
Results: The median age of the 287 study patients was 65 (19–101) years; 78% were female. Seventy percent had
community-acquired bacteriuria. One-hundred ten (38.3%) patients had ASB and 177 (61.7%) had symptomatic
urinary tract infection (sUTI). Asymptomatic patients were more likely than symptomatic patients to have congestive
heart failure (p = 0.03), a history of myocardial infarction (p = 0.01), chronic pulmonary disease (p = 0.045), peripheral
vascular disease (p = 0.04), and dementia (p = 0.03). Patients with sUTI were more likely to be neutropenic at the
time of bacteriuria (p = 0.046). Chronic pulmonary disease [OR 2.1 (95% CI 1.04, 4.1)] and dementia [OR 2.4
(95% CI 1.02, 5.8)] were independent predictors for asymptomatic bacteriuria. Absence of pyuria was not predictive
of ASB. None of the individual virulence genes tested were associated with ASB nor was the total number of genes.
Conclusions: Asymptomatic E. coli bacteriuria in hospitalized patients was frequent and more common in patients
with dementia and chronic pulmonary disease. Bacterial virulence factors could not discriminate symptomatic from
asymptomatic bacteriurias. Asymptomatic E. coli bacteriuria cannot be predicted by virulence screening.
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Background
Escherichia coli is the most frequent pathogen to cause
symptomatic urinary tract infection (sUTI) but can also
lead to asymptomatic bacteriuria. Asymptomatic bacteri-
uria (ASB) denotes bacterial colonization of the urogeni-
tal tract without subjective or systemic host responses.
ASB screening and treatment are recommended only
during pregnancy [1] and in the preoperative evaluation
of men before urological procedures [2], circumstances
where preemptive antibiotic administration decreases
the risk of infectious complications [3]. Despite these
recommendations, overuse of antibiotics for ASB is
common and clearance of bacteriuria is often transient,
leading to further treatment courses [4]. Inappropriate
antibiotics result in increased healthcare costs and foster
antimicrobial resistance [5]; they can even eliminate the
protective effect that ASB may have against recurrent
UTIs [6]. These issues have led to calls for assessing
hospitals’ performance in reducing inappropriate anti-
biotic use nationwide [7].
Surprisingly few studies have compared patients with
symptomatic bacteriuria to patients with ASB to identify
patient-level risk factors for symptomatic presentation
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or differences in bacterial virulence factors [8-12]. Re-
sults from these studies have been inconsistent,
reporting either a variety of virulence factors associated
with symptomatic bacteriuria [8-11] or no association
[12]. We found no previous studies addressing clinical
risk factors. Urine cytokines such as interleukin 6 and 8
may be lower in ASB in certain populations [13,14], but
an objective test to discriminate ASB from symptomatic
bacteriuria is not commercially available. A better under-
standing of what differentiates ASB from symptomatic
bacteriuria could be particularly helpful in patients who
are unable to report symptoms, such as intubated
patients or those with altered mental status. Here, we
used a prospective cohort of patients with E. coli bacteri-
uria as identified by clinicians in a hospital setting. The
purpose of our study was to characterize host and
pathogen factors associated with E. coli ASB that could
subsequently be used in predictive models, lead to the
development of bedside tests to distinguish ASB from
sUTI, or guide treatment decision-making.
Methods
Study design, data collection, and definitions
We performed a prospective cohort study of patients
with E. coli bacteriuria from August 1st 2009 until July
31st, 2010, at Barnes-Jewish Hospital (BJH), a 1250-bed
teaching hospital in eastern Missouri. All adult patients
admitted to BJH who presented with E. coli bacteriuria
at time of admission or developed it subsequently were
considered for enrollment. Urine cultures were taken at
the discretion of the treating physician. The cut-off for
significant bacteriuria employed in our hospital micro-
biology laboratory was 5×104 colony-forming units/ml in
non-catheterized and 5×103 in catheterized patients. The
bacteriuria was classified as community-acquired if the
first positive urine culture occurred within 48 hours of
admission. Patients transferred from outside hospitals or
long-term care facilities were not considered to have
community-acquired bacteriuria. Polymicrobial UTIs
were excluded, as were patients who had concurrent
bloodstream infection with an organism other than
E. coli. We reviewed medical records of those who met
inclusion criteria for demographics, medical and
urogenital history, and computed Charlson comorbidity
and McCabe severity of illness scores. The patients’
clinical, laboratory, radiological, and pharmacy data were
prospectively reviewed during the admission, including
information on all urine and blood cultures. Medication
information was entered as start and stop dates and
times for each antibiotic with Gram-negative activity.
We classified E. coli bacteriurias based on the patients’
urinary symptoms with the objective of determining
distinctive features of asymptomatic bacteriuria (ASB). ASB
was defined as absence of urinary symptoms. Symptomatic
urinary tract infection (sUTI) included cystitis, defined as
presence of dysuria, frequency, urinary retention, or lower
abdominal pain (without signs of pyelonephritis); or pyelo-
nephritis, defined as the presence of flank pain or tender-
ness and/or fever. We defined unclassifiable bacteriuria as
bacteriuria in a patient who did not fit any of the above
criteria or could not report symptoms (e.g., intubation,
altered mental status); these patients were excluded from
the analysis. If a urinary catheter had been in place in the
48 hours preceding the positive urine culture the bacteri-
uria was considered as catheter-associated. Past urogenital
surgery included all surgeries that resulted in anatomical
alteration (e.g. nephrectomy, neobladder formation, pros-
tatic resection, and hysterectomy).
Outcomes of interest were sepsis, sepsis-induced
hypotension, E. coli bacteremia, transfer to the ICU
within 72 hours of the bacteriuria, length of hospital stay
after detection of bacteriuria, and in-hospital mortality.
Sepsis and sepsis-induced hypotension were defined
using established criteria [15]. Blood cultures were
drawn at the discretion of the treating physician and had
to occur within ±1 day of the bacteriuria. Adequacy of
antibiotic therapy was defined as pathogen-directed
treatment with antibiotics matching susceptibilities.
Laboratory analyses
We identified the E. coli isolates from urine cultures of
eligible patients in the hospital microbiology laboratory
and stored them at −80°C in skim milk. Isolates were
processed at the Center for Molecular and Clinical
Epidemiology at the School of Public Health, University
of Michigan, Ann Arbor, MI. Bacterial DNA was
extracted using QIAamp DNA mini kit (QIAGEN,
Valencia, CA). DNA probes for the following virulence
genes were designed: Hemolysin (hlyA), P family of
fimbriae (prf ) [this primer detects all pap adhesions], Dr
family of adhesins (Dr), S fimbriae (sfaS), cytotoxic
necrotizing factor (cnf1), aerobactin iron uptake system
(iutA), salmochelin iron uptake system (iroN), yersi-
niabactin iron uptake system (fyuA), group II capsule
gene (kpsMT), irgA homologue adhesin (iha), uropa-
thogenic specific protein (usp), outer membrane protein
(ompT), the secreted autotransporter toxin (sat), and for
chuA (outer heme receptor). The presence of these viru-
lence genes was determined by dot-blot hybridization
with fluorescent-labeled probes and a fluorescein-based
detection system as described elsewhere [16]. To screen
large numbers of isolates in short time periods, we used a
microarray system for high-throughput dot-blot hybri-
dization [17]. The frequency of specific virulence genes
was compared between symptomatic and asymptomatic
patients. Furthermore, bacterial isolates were compared
regarding antimicrobial susceptibility patterns.
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Sample size calculations and statistical analysis
We based our sample size calculations on two studies
that reported 34-44% of bacteriuric patients had symp-
toms and that males were slightly more likely to have
sUTI [8,18]. Assuming that male patients account for
65% in the sUTI and for 45% in the ASB group and
given a 0.05 significance level and 80% power, we esti-
mated that we would require 88 vs. 132 patients in the
two groups, respectively (EpiInfo 3.3.2; accessed at www.
cdc.gov/epiinfo/).
Data analysis was performed using SPSS 18 (SPSS Inc.,
Chicago, IL). Univariate comparisons among categorical
variables were performed using the χ2 test or Fisher’s
exact test as appropriate. Comparisons among conti-
nuous independent variables were performed using
Student’s t test or Mann Whitney U test as appropriate.
A two-sided p value of <0.05 was considered significant.
Variables found to have a p ≤ 0.1 on univariate testing
were simultaneously entered into a multivariate logistic
regression model. The model was tested with goodness-
of-fit measures.
The study was approved both by the Washington
University Human Research Protection Office and the
University of Michigan Institutional Review Board. We
obtained a waiver of informed consent from both
Boards.
Results
We identified 337 patients with E. coli bacteriuria during
the study period. Of these, 50 (14.8%) were excluded
because they were considered unclassifiable (e.g., intubated
patients or patients with acutely altered mental status who
were unable to report symptoms). Among the remaining
287 patients, 110 (38.3%) were classified as having asymp-
tomatic bacteriuria, and 177 (61.7%) as having symptom-
atic UTI. Two hundred and twenty-five patients were
female (78.4%), and 169 (58.9%) were white (Table 1). Age
had a bimodal distribution, with a small peak between 20
and 25 years and a larger peak between 60 to 80 years; the
median age was 65 years (range, 19–101). Among symp-
tomatic patients, 70 (39.4%) had cystitis, and 107 (61.6%)
pyelonephritis. In this group of symptomatic patients, 91
(51.4%) were tested for bloodstream infection, and 20 had
positive blood cultures. Among asymptomatic patients, 35
(31.8%) had blood cultures taken, and one was positive for
E. coli.
Comparison of patient risk factors for asymptomatic
bacteriuria
Asymptomatic patients were more likely than symptom-
atic patients to have congestive heart failure (p = 0.03), a
history of myocardial infarction (p = 0.01), chronic pul-
monary disease (p = 0.045), peripheral vascular disease
(p = 0.04), and dementia (p = 0.03) (Table 1). Conversely,
patients with symptomatic UTI were more likely to be
neutropenic at the time of bacteriuria (p = 0.046). Sub-
sets of catheter-associated bacteriuria were similar in the
two groups (p = 0.5). Also, there was no difference in the
subset of complicated bacteriurias between the groups
[95 (86%) among asymptomatic vs. 153 (86%); p = 1.0].
Comparison of virulence factors for asymptomatic
bacteriuria
We also compared the prevalence of virulence genes in
the bacterial isolates from both groups (see Table 2). The
most frequently detected virulence factors were chuA
(83.3%), fyuA (82.9%), and ompT (79.8%). There were no
statistically significant differences encountered. The total
number of virulence factors per isolate did not differ
between asymptomatic [median 6.5 (range, 0–13)] and
symptomatic [median 7 (0–12)] patients (p = 0.2).
When comparing the resistance pattern of bacterial
isolates there was no difference in resistance to the most
frequently used antibiotics ciprofloxacin [41/110 (37%)
among sUTI vs. 57/177 (32%) among ASB patients;
p = 0.4] or trimethoprim/sulfamethoxazole [32/110 (29%)
vs. 45/177 (25%); p = 0.5].
Multivariate analysis of risk factors for asymptomatic
bacteriuria
We performed a multivariate analysis of risk factors for
ASB entering variables that had a p ≤0.1 in univariate
analysis. Based on the numbers of ASB cases we
intended to include a maximum of 10–12 variables into
the model. Neutropenia, congestive heart failure, chronic
pulmonary disease, history of myocardial infarction,
peripheral vascular disease, dementia, and pyuria were
entered into the model. Chronic pulmonary disease [OR
2.1 (95% CI 1.04, 4.1)] and dementia [OR 2.4 (95% CI
1.02, 5.8)] were independent predictors for asymp-
tomatic bacteriuria. Pyuria was not associated with
symptomatic UTI. The Hosmer-Lemeshow test indicated
a good fit for the data (p = 0.3).
Clinical outcomes
There was no difference in the proportion of patients
requiring admission to the intensive care unit between
the two groups [11 (10%) ASB vs. 22 (12%) sUTI;
p = 0.5]. Symptomatic UTI patients were more likely to
meet sepsis criteria [108 (61%) vs. 38 (35%); p < 0.001] and
develop sepsis-induced hypotension [41 (23%) vs. 7 (6%);
p < 0.001]. Twelve patients died during their hospital
admission (4.2%). There was no difference in mortality
(p = 0.5) nor in length of hospital stay after the bacteriuria
whether it was symptomatic or not (p = 0.2).
Fewer ASB patients received pathogen-directed anti-
biotic treatment during the hospitalization [89 (81%) vs.
168 (95%); p < 0.001]. Among those receiving antibiotic
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Table 1 Comparison of 110 patients with asymptomatic bacteriuria to 177 patients with symptomatic urinary tract
infection due to E. coli
Variable Asymptomatic
bacteriuria (n = 110)
Symptomatic urinary tract
infection (n = 177)
p value Adjusted odds ratio
(95% CI)*
n (%) n (%)
Gender (male) 19 (17) 43 (24) 0.2
Age (years, median, range) 67 (20, 100) 64 (19, 101) 0.1
Race (white) 68 (62) 101 (57) 0.4
Body mass index (kg/m2, mean, ±SD) 28.9 (±8.4) 28.9 (±9.9) 1.0
Diabetes mellitus 39 (36) 53 (30) 0.3
Renal insufficiency (Cr > 1.5 mg/dl) 23 (21) 37 (21) 1.0
Any malignancy 28 (26) 44 (25) 0.9
Any transplant 3 (3) 9 (5) 0.3
Neutropenia at time of bacteriuria (ANC <1000/ul) 0 7 (4) 0.046
Pregnancy 5 (5) 8 (6) 1.0
Congestive heart failure 26 (24) 24 (14) 0.03
Myocardial infarction 23 (21) 18 (10) 0.01
Chronic pulmonary disease 25 (23) 24 (14) 0.045 2.1 (1.04-4.1)
Peripheral vascular disease 9 (8) 5 (3) 0.04
Oral steroid medication 6 (5) 15 (8) 0.3
Dementia 15 (14) 11 (6) 0.03 2.4 (1.02-5.8)
History of cerebrovascular accident 24 (22) 36 (20) 0.8
Hemi- or paraplegia 13 (12) 14 (8) 0.3
Functional or anatomical urinary tract abnormalities 31 (28) 54 (31) 0.7
Voiding dysfunction 26 (24%) 54 (31%) 0.2
Benign prostatic hyperplasia (n = 62) 3/19 (16) 15/43 (35) 0.1
History of urogenital surgery 30 (27) 61 (34) 0.8
Urological procedure this admission 0 5 (3) 0.2
Charlson comorbidity index (mean, ±SD) 3.1 (±2.6) 2.8 (±2.8) 0.2
McCabe severity-of-illness score (median, range) 1 (1, 2) 1 (1, 3) 0.2
Cystitis - 70 (39) -
Pyelonephritis - 107 (62) -
Sepsis 38 (35) 108 (61) <0.001
Sepsis-induced hypotension 7 (6) 41 (23) <0.001
Community-acquired bacteriuria 75 (68) 127 (72) 0.5
Urinary catheter-associated bacteriuria 22 (20) 30 (17) 0.5
Urinalysis with pyuria (>10 WBC/hpf) 65 (63) 121 (74) 0.1
Isolate resistant to ciprofloxacin 57 (32%) 41 (37%) 0.4
Isolate resistant to trimethoprim/ sulfamethoxazole 45 (25%) 32 (29%) 0.5
Outcomes
Pathogen-directed antibiotic treatment 89 (81) 168 (95) <0.001
Length of hospital stay (mean, ±SD) 5.5 (±7.7) 6.6 (±7.5) 0.2
In-hospital mortality 4 (3.6) 8 (5) 0.5
NOTE. CI = confidence interval. SD = standard deviation. Cr = creatinine. ANC = absolute neutrophil count. WBC = white blood cells. HPF = high-power field.
* The variables included in the final model were neutropenia, congestive heart failure, chronic pulmonary disease, history of myocardial infarction, peripheral
vascular disease, dementia, and pyuria.
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treatment, the mean time from detection of bacteriuria
to receipt of appropriate antibiotics was shorter for
symptomatic patients [15.9 hours (±26.8) vs. 22.4 hours
(±23.2); p = 0.07). We did, however, not compare treat-
ment variation in the antibiotic therapy as part of this
analysis and antibiotic prescriptions at hospital discharge
were not taken into account.
Discussion
Why E. coli bacteriuria is associated with urinary tract
symptoms in some instances but not in others remains
incompletely understood. This knowledge gap may
explain why E. coli bacteriuria is often treated with antibi-
otics independent of any symptoms [19]. Overtreatment
in turn generates added cost and can facilitate the devel-
opment of antibiotic resistance. It would therefore be
invaluable if we had tools to differentiate between symp-
tomatic infection and asymptomatic bacteriuria (and to
understand which bacteriurias result in morbidity in
patients who are unable to report symptoms). Here, we
report a comparison of patient characteristics and viru-
lence factors between symptomatic and asymptomatic
patients with E. coli bacteriuria. While we found inde-
pendent clinical predictors for asymptomatic bacteriuria
(chronic pulmonary disease, dementia) no virulence pat-
tern could be associated with the corresponding E. coli
isolates.
To our knowledge there are no published studies of
patient characteristics to differentiate ASB from symp-
tomatic UTI. We found the comorbidities chronic
pulmonary disease and dementia to be associated with
asymptomatic bacteriuria. It is conceivable that underlying
dementia resulted either in poor symptom recognition by
the affected patients or may have impaired their ability to
report symptoms. ASB is also much more prevalent in
elderly long-term care residents [20] who are prone to
cognitive deficits, and cognitive changes may be a risk
factor for ASB [21]. Other potential contributors are poor
perineal hygiene and incomplete bladder emptying. It is
less clear why chronic pulmonary disease should be asso-
ciated with ASB; this may be due to different screening
practices in medical subspecialties or a spurious finding.
Those with ASB may finally represent a group of patients
in which it was more difficult to find a diagnosis and urine
cultures were part of the broad work-up.
A small number of studies have determined differences
in bacterial virulence factors between strains causing
ASB and sUTI. Mabbett et al. compared 57 ASB strains
to 45 cystitis/pyelonephritis strains not only in regard to
their virulence genes but also in gene product expression
and epithelial adhesion studies [8]. PapGII (47% vs. 16%)
and afa (29% vs. 11%) were associated with sUTI as were
hemolysin expression, siderophore expression, and
adhesion to epithelial cells. However, the authors noted
that ASB and sUTI strains tended to be phylogenetically
related. The latter finding was confirmed by Takahashi
et al. who investigated virulence factors in 283 E. coli
urinary isolates from a hospital in Japan, and also saw a
similar distribution of serotypes across ASB and sUTI
isolates. The virulence genes iha (31% vs. 13%), ompT
(82% vs. 70%) and PAI, which refers to the so-called
genomic “pathogenicity island” (65% vs. 50%), were all
significantly more frequent in strains causing sUTI [9].
Although ompT was a common virulence gene in our
similar-sized cohort, the sUTI strains we analyzed did
not carry ompT more frequently (83% vs. 76%). A num-
ber of smaller studies in subpopulations like pregnant
women and patients with spinal cord injuries found
other virulence factors to be associated with symptom-
atic infections [10,11] or were negative [22]. In addition
to the bacterial characteristics mentioned above, there
have been reports that ASB strains can be identified
based upon their capability to form biofilms in vitro
[23], for which we did not screen our isolates. With 287
patient samples our cohort is one of the largest to date;
however, we did not find any virulence gene to predo-
minate in the subset of symptomatic patients. One of
the possible explanations for this negative finding is that
virulence genes in ASB may carry deletions that block
gene expression [24-26]; therefore, ASB strains may look
more virulent by genotype than they actually are in vivo.
Another possibility is that virulence factors other than
those we examined are more relevant in determining
pathogenicity [27]. Yet another possibility is that the
Table 2 Comparison of virulence genes present in E. coli
isolates from 287 patients with asymptomatic bacteriuria
or symptomatic urinary tract infection
Variable Asymptomatic
bacteriuria
(n = 110)
Symptomatic
urinary tract
infection (n = 177)
p value
n (%) n (%)
chuA 90 (81.8) 149 (84.2) 0.6
fyuA 91 (82.7) 147 (83.1) 0.9
ompT 83 (75.5) 146 (82.5) 0.15
usp 79 (71.8) 117 (66.1) 0.3
kpsMT (group II capsule) 59 (53.6) 95 (53.7) 1.0
iucD 49 (44.5) 89 (50.3) 0.3
iha 51 (46.4) 70 (39.5) 0.3
sat 43 (39.1) 75 (42.4) 0.6
prf (P family of fimbriae) 28 (25.5) 51 (28.8) 0.5
iroN 25 (22.7) 40 (22.6) 1.0
hlyA 19 (17.3) 38 (21.5) 0.4
sfa 20 (18.2) 30 (16.9) 0.8
cnf1 13 (11.8) 20 (11.3) 0.9
Dr 6 (5.5) 14 (7.9) 0.4
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major determinant of symptom development is unre-
lated to pathogen factors, but due to unmeasured factors
such as the host’s innate immune response [28-30].
Future research should incorporate studies of the host’s
defense mechanisms (e.g., toll-like receptor polymor-
phisms) into a multi-faceted analysis of symptom devel-
opment in bacteriuria.
There are a number of limitations to our study.
Including only patients that were tested for and found to
have bacteriuria may have introduced selection bias. We
suspect that this bias was particularly relevant for ASB
patients which were included despite an indication for
culturing. Symptoms at the time of bacteriuria were
taken from hospital charts entered by physicians and
nurses; therefore patient symptoms may have been
underreported. We did not obtain urine samples to
determine whether virulence factors were expressed
in vivo, nor test gene expression of the bacterial isolates
in vitro. Also, we elected to test for a specific set of
virulence factors but may have missed others that are
not identified yet. Blood cultures were ordered by the
treating physicians and may have missed septic or febrile
patients at risk for bacteremia. Lastly, we did this study
at a single tertiary-care center and the findings may not
be generalizable to other settings. This also goes for the
high levels of resistance to the most commonly used
antimicrobials that we encountered here.
Conclusions
In summary, our study is the largest cohort study to
analyze both patient and pathogen factors associated with
asymptomatic versus symptomatic bacteriuria, was con-
ducted prospectively and included both genders. Novel
predictive factors (chronic pulmonary disease, dementia)
were identified that could serve for clinical decision-
making on antibiotic treatment. Host susceptibility (i.e.,
characteristics of an individual’s innate immune system)
may be more relevant for symptom development in E. coli
bacteriuria than virulence determinants.
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